• Explore /
  • Poster
  • / Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

Abstract Poster

Authors

null

Richard D. Carvajal

Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

Richard D. Carvajal , Takami Sato , Marcus O. Butler , Joseph J. Sacco , Alexander Noor Shoushtari , Jessica Cecile Hassel , Alexandra Ikeguchi , Leonel Fernando Hernandez-Aya , Matthew Rioth , Omid Hamid , Josep M. Piulats , Jason J. Luke , Douglas Buckner Johnson , Serge Leyvraz , Enrique Espinosa , Laura Collins , Michelle L. McCully , Sarah Lockwood , Shaad Essa Abdullah , Paul Nathan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02570308

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9531)

DOI

10.1200/JCO.2021.39.15_suppl.9531

Abstract #

9531

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alexandra Ikeguchi

First Author: Marlana Orloff

First Author: Mark R. Middleton

First Author: Takami Sato